ACAnna I. Chernyavina

Anna I. Chernyavina

*This is an algorithmically generated author record based on publicly available information.

Anna I. Chernyavina has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictors of the formation of long-term post-COVID syndrome with the main symptom of dyspnea in patients with a severe course of a new coronavirus infection

    by Olga V. Masalkina, Anna I. Chernyavina, Natalia A. Koziolova, Elena A. Polyanskaya

    Objective: to determine the predictors of the formation of long-term post-COVID syndrome with the main symptom of dyspnea in patients with severe new coronavirus infection (NCVI). Materials and methods: A single-stage screening clinical study with a retrospective assessment of the course of NCVI was carried out. Over the course of 4 years, 878 patients went to the clinic for shortness of breath 3 or more months after suffering from NKVI. Long-term post-COVID syndrome was verified in 205 (23.35 %) patients with the main symptom of dyspnea without distinction by sex, who were included in the study according to the inclusion and non-inclusion criteria. Hospitalization during NCVI was defined as a severe course of infection. Depending on the presence or absence of hospitalization during NCVI, patients with dyspnea and long-term post-COVID syndrome included in the study were divided into two groups. The first group included 103 patients with dyspnea and prolonged post-COVID syndrome and severe NCVI, the second group included 102 patients with mild NCVI and did not require hospitalization. Results: The mean age of the patients was (57.15 ± 12.4) years. Clinical and anamnestic analysis showed that regardless of the severity of the NCVI suffered, the group of patients with dyspnea after the onset of NCVI after 7.3 [3.2; 12.8] months were comparable in terms of sex, age, cardiovascular risk factors, concomitant pathology, structure, frequency and doses of constantly used drugs, indicators reflecting the state of the heart, filtration function of the kidneys, ferrokinetics, markers of nonspecific inflammation. The severity of dyspnea according to the mMRC 2 questionnaire in patients with a history of severe NCVI is associated with an increase in the odds ratio (OR) the formation of long-term post-COVID syndrome by 3.704 times, relative risk (RR) by 1.630 times; with a decrease in SaO2 ≤ 96 % after a 6-minute walking test, the OR increased by 5.828 times, the RR by 1.891 times; with lung damage of more than 45 % during the acute period of NCVI, the OR increased 2.772-fold, the RR – 1.981-fold; when anxiety and depression occurred more than 6 points on the HADS scale, the OR increased by 12.142 times, the RR – by 2.839 times; with the development of cognitive impairment on the MMSE scale ≤ 27 points, the OR increased 6.117-fold, the RR – 4.528-fold; when the N-terminal fragment of the brain natriuretic propeptide (NT-proBNP) increased by more than 139 pg/ml, the OR increased by 5.553 times, and the RR increased by 3.962 times; at a blood concentration of caspase 6 of more than 28.8 pg/ml, the OR increased 4.861-fold, and the RR increased 3.962-fold. Conclusion: The course of long-term post-COVID syndrome in patients who have had severe forms of NCVI is characterized by more pronounced shortness of breath, the presence of multiple symptoms that worsen the quality of life, and a statistically more significant decrease in tolerance to physical activity. The presence and severity of anxiety, depression, cognitive impairment, increased levels of myocardial stress assessed by NT-proBNP and panoptosis assessed by caspase level 6 in the normal range are predictors of the development of long-term post-COVID syndrome in patients with dyspnea who have experienced severe NCVI in the acute period.

  • Open Access

    Predictors of the Development of Newly Diagnosed Chronic Heart Failure in Patients with Shortness of Breath in Long-Term Post-COVID Syndrome

    by O. V. Masalkina, A. I. Chernyavina, N. A. Koziolova, E. A. Polyanskaya, S. V. Mironova, E. V. Ulybina

    Aim To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome. Material and methods This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified. At the second stage, a group of 192 patients with two or more diagnostic criteria for CHF who met the inclusion criteria and had no exclusion criteria was selected. The patients selected for the second stage were divided into two groups based on the blood concentration of the N-terminal pro-brain natriuretic peptide (NT-proBNP): the first group included 108 patients with a NT-proBNP value of ≤125 pg/ml, and the second group of 84 patients with a NT-proBNP value of >125 pg/ml. Results Newly diagnosed CHF was found in 84 (9.57%) patients with dyspnea, who sought medical care for long-term post-COVID syndrome with three or more diagnostic criteria (symptoms/signs, structural and functional changes in the heart according to echocardiography, increased NT-proBNP concentration), mainly with preserved left ventricular ejection fraction (LVEF) (97.9%). With an increase in the left ventricular myocardial mass index (LVMI) >110 g/m 2 , the odds ratio (OR) of developing newly diagnosed CHF increased by 2.201 times and the relative risk (RR) increased by 1.801 times; with the development of pneumonia associated with COVID-19, the OR increased by 45.5% and the RR by 70.8%; with the development of pneumonia requiring hospitalization in patients with COVID-19, the OR increased by 34.7% and RR by 54.7%; with an increase in the erythrocyte sedimentation rate >11 mm/h, the OR increased by 41.7% and the RR by 74.1%; with a decrease in the blood concentration of potassium 178 μg/ml in combination with an iron transferrin saturation ratio 28.2 pg/ml, the OR increased by 28.8% and the RR by 35.4%. Conclusion Among 878 outpatients who sought treatment at the polyclinic for shortness of breath in long-term post-COVID syndrome, the prevalence of newly diagnosed CHF verified by three or more diagnostic criteria was 9.57%, mainly with preserved LVEF. The development of CHF in these patients was related with more severe forms of previous COVID-19 complicated by pneumonia and requiring hospitalization, an increase in LVMI to > 110 g/m 2 , activation of low-grade nonspecific inflammation, metabolic disorders due to a decrease in potassium even within the normal range, latent iron deficiency, and an increase in the PANoptosis processes.


  • Open Access

    Features of the State of the Collagenolysis System and risk factors of Its Changes in Patients with Long-Term Post-COVID Syndrome

    by O. V. Masalkina, E. A. Polyanskaya, N. A. Koziolova, A. I. Chernyavina

    Objective: to assess the state of the collagenolysis system in patients with long-term post-COVID syndrome, to determine the features and risk factors of its changes. Materials and methods. The study included 178 patients who had had a new coronavirus infection (NCVI) 12 weeks or more ago, depending on the presence or absence of symptoms of long-term post-COVID syndrome, patients who had NCVI 12 or more weeks ago were divided into 2 groups: the first group consisted of 88 patients with Long-covid symptoms; the second group consisted of 90 subjects without any symptoms of Long-covid. Results. The median period after NCVI was 8.5 [3.6; 12.4] months. In all patients who underwent NCVI, tissue inhibitor of matrix metalloproteinase type 1 (TIMP1) was higher than the reference value (135 pg/ml). In the patients of the first group, TIMP1 was lower than in the second group: 315.5 [145.0; 620.0] pg/mL vs. 513.5 [220.0; 865.0] pg/mL (p < 0.001). Therefore, in long-term post-COVID syndrome, a collagenolytic pattern develops against the background of an increased risk of fibrosis. Conclusion. In patients who have undergone NCVI with a long-term post-COVID syndrome, the state of the collagenolysis system is characterized by the development of a collagenolytic pattern against the background of the prevailing processes of collagen formation in comparison with asymptomatic patients who had NCVI 12 weeks ago or more, which can be considered as a pathogenetic mechanism for the formation of “Long Covid”.

  • Peculiarities of the clinical course and risk factors of long-lasting post-COVID syndrome in patients with shortness of breath

    by Masalkina O.V. Masalkina, Polyanskaya E.A. Polyanskaya, Koziolova N.A. Koziolova, Chernyavina A.I. Chernyavina, Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia

  • Predictors of anemia development in long-lasting post-COVID syndrome

    by Koziolova N.A. Koziolova, Chernyavina A.I. Chernyavina, Masalkina O.V. Masalkina, Sosnin D.YU. Sosnin, Academician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of Russia

  • Open Access

    Real-world data on managing patients with coronary artery disease and multifocal atherosclerosis. Results of the 12-month international clinical registry of patients with identified multifocal atherosclerosis in the Russian Federation and Eurasian countries (KAMMA)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, А. Ю. Васькин, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study real-world data on managing patients with coronary artery disease (CAD) and multifocal atherosclerosis (MFA) for 12 months by outpatient cardiologists.Material and methods. KAMMA is a real-world registry organized by the Eurasian Association of Therapists. The main branch included men and women over 18 years of age with confirmed atherosclerosis in two or more arterial systems and one or more risk factors for atherosclerosis. The start date for patient recruitment was February 1, 2022 and the end date was November 27, 2022. The design included 3 following visits: 1 — baseline, 2 — after 6 months, 3 — after 12 months. Twentyeight research centers were located in 7 federal districts of the Russian Federation, as well as in the Republics of Kazakhstan, Uzbekistan and Belarus.Results. A patient population (n=2905) was formed, all of whom had verified CAD. The mean age was 66,0 [59,0; 72,0] years (men — 60,3%). Low-density lipoprotein cholesterol decreased by 20,4% over 12 months, while non-high-density lipoprotein cholesterol — by 12,7%. Over 12 months, lipid-lowering therapy did not undergo significant changes. Statin monotherapy was maintained in 83%, of which only 53,7% of patients received high-dose therapy. Combined statin+ezetimibe therapy was used in 12,4%, while statin+ezetimibe+PCSK9 inhibitor — in 4,6%. During the 1-year follow-up, antithrombotic therapy was not enhanced. Low prescription rate of combination therapy with antiplatelet agents (15,7%) and low-dose rivaroxaban and acetylsalicylic acid (7,9%) remained. By the follow-up end, a high incidence of major adverse cardiovascular events (8,8%) was registered in patients included in the KAMMA registry.Conclusion. Despite the fact that patients with MFA have a very high cardiovascular risk, routine management of these patients is characterized by high clinical inertia. During the 1-year follow-up, lipid-lowering and antithrombotic therapy was not properly strengthened, due to which the target levels of key lipid profile parameters were not achieved and a high rate of major adverse cardiovascular events was observed in patients included in the registry.


  • Factors influencing caspase-6 levels in patients with dyspnea associated with long COVID

    by Olga V. Masalkina, Anna I. Chernyavina, Natalya A. Koziolova, Elena A. Polyanskaya

    BACKGROUND: Apoptosis is a genetically programmed form of cell death. It is essential for maintaining homeostasis in the body. A key feature of apoptosis is the maintenance of normal cell population, with caspases playing a central role and potentially contributing to the pathogenesis of specific long COVID phenotypes. Identifying the role of caspases and their association with clinical markers may provide additional evidence for the causes of this syndrome. AIM: To determine the role of caspase-6 in patients with dyspnea or its equivalents in long COVID. METHODS: A single-center, cross-sectional observational study was conducted over a 3-year period, when 878 patients sought medical care for dyspnea or its equivalents at an outpatient clinic, with 186 patients included in the study. RESULTS: All patients in the study had caspase-6 levels within the reference range. Caspase-6 concentration in the long COVID group (group 1, n = 86) was significantly lower than that in the control group (group 2, n = 100) with no history of COVID-19. To identify risk factors for decreased apoptotic activity and increased pro-inflammatory responses, 86 patients with long COVID and dyspnea were stratified into two subgroups based on caspase-6 levels: 33 patients (38.4%) with caspase-6 26.5 pg/ml and 53 patients (61.6%) with caspase-6 ≤ 26.5 pg/ml. Severe COVID-19 pneumonia was associated with a nearly 7-fold increase in the relative risk (RR) of reduced apoptotic activity and an increase in pro-inflammatory responses in the post-COVID period: RR 6.85; 95% confidence interval (CI) 1.02–143.74. It also increased the risk of elevated N-terminal pro-B-type natriuretic peptide level 120 pg/ml by more than 2-fold (RR 2.41; 95% CI 1.27–5.14), carotid-femoral pulse wave velocity 10.6 m/s by 4-fold (RR 4.10; 95% CI 1.45–11.77), aortic pulse wave velocity 8.3 m/s by 3-fold (RR 3.22; 95% CI 1.31–9.62), increased ferritin level 152.5 ng/ml. It reduced transferrin saturation 19.8% by 2.5-fold (RR 2.49; 95% CI 1.23–5.75), and increased tissue inhibitor of metalloproteinases-1 level 376.1 ng/ml by 69% (RR 1.69; 95% CI 1.10–2.72). CONCLUSION: Long COVID-related dyspnea is associated with reduced caspase-6 levels, which correlate with impaired apoptotic activity and heightened inflammatory responses. Proposed pathophysiological mechanisms underlying caspase-6 deficiency include activation of myocardial stress pathways, increased collagen deposition, hyperferritinemia, and arterial stiffness.

  • Open Access

    The condition of target organs in patients with hypertension after new coronavirus infection

    by N. M. Syuzeva, N. A. Koziolova, A. I. Chernyavina, O. V. Masalkina

    Objective. To determine the risk factors for the development of new coronavirus infection (NCVI) in patients with hypertension (AH) and to assess the condition of target organs depending on the course of NCVI. Materials and methods. A screening clinical observational comparative study is presented. For a 2-year period 186 patients with a history of AH or with a first-time BP increase who consulted a general practitioner in an outpatient department were sequentially included into the study in accordance with the inclusion and non-inclusion criteria. The patients were divided into two groups depending on the presence of NCVI: the first group consisted of 100 patients with AH or first-onset AH who had had NCVI; the second group contained 86 patients with AH or first-time AH without a history of NCVI. All patients with AHunderwent a comprehensive routine clinical examination with an assessment of target organ damage in accordance with clinical guidelines within 14 days after visiting the polyclinic with an assessment of the data of the outpatient card and other medical documents to register concomitant diseases and conditions, as well as the features of the course of NCVI. Results. Vaccination against NCVI in patients with AH reduces the relative risk (RR) of the development not only of NCVI by 87 %, but NCVI-pneumonia with hospitalization and prolonged post-COVID syndrome as well. It has been proved that obesity with a body mass index of 30 g/m2, atherosclerosis of any localization, type 2 diabetes mellitus increase the RR of the development of various forms of NCVI, including a prolonged course of more than 12 weeks. Newly diagnosed chronic heart failure (CHF), verified not only by clinical symptoms, but also by echocardiography and N-terminal fragment of brain natriuretic propeptide (Nt-proBNP) concentration in the blood, increases the RR of the development of NCVI by 48.2 %, NCVI- pneumonia with hospitalization, and the prolonged course of NCVI by more than 2 times. An increase in Nt-proBNP 125 pg/ml in patients with AH even without CHF is associated with the development of various forms of NCVI, including post-COVID syndrome. The use of renin-angiotensin-aldosterone system (RAAS) blockers, dual combined antihypertensive therapy in patients with AH reduced the RR of the development of both NCVI, NCVI-pneumonia with hospitalization and the prolonged course of NCVI on an average by 30 to 50 %. The use of sulfonylureas and/or insulin therapy in patients with AH and type 2 diabetes mellitus was associated with an increase in the RR of the development of NCVI by 73.6 %, the RR of the development of NCVI-pneumonia with hospitalization was more than 4 times higher, and a prolonged course of NCVI almost 3 times higher. Average daily pulse blood pressure and abnormal patterns of circadian rhythm of SBP and DBP were associated with an increase in RR of both acute and chronic forms of long-term NCVI. NСVI- pneumonia with hospitalization and post-COVID syndrome are associated with an increase in the RR of pathological changes in all target organs in patients with AH in comparison with patients who did not have any complications after NCVI. Conclusion. Known risk factors for the development of various forms of NCVI, including its prolonged course in patients with AH, have been confirmed and new ones have been revealed. It has been determined that NCVI with a severe course and post-COVID syndrome are associated with pathological changes in all target organs in patients with AH after NCVI.

  • Open Access

    Predictors of the development of abnormal patterns of circadian blood pressure rhythm in patients with hypertension after a new coronavirus infection

    by N. M. Syuzeva, O. V. Masalkina, N. A. Koziolova, A. I. Chernyavina

    Objective. To determine the predictors of the development of abnormal patterns of circadian blood pressure (BP) rhythm in patients with arterial hypertension (AH) after a new coronavirus infection (NСVI). Materials and methods. The study is a comparative clinical research of the same patients with hypertension before and after NCVI with retrospective evaluation of the data. Within 2 years from 842 patients with cardiovascular risk factors, according to the inclusion and non-inclusion criteria 70 patients with target levels of office BP, home monitoring and 24-hour blood pressure monitoring (ABPM) on the background of a continuous antihypertensive therapy were included in the study. Abnormal patterns of circadian BP were recorded after NCVI during ABPM in all of them. All patients with hypertension underwent a complete examination before and after NCVI. Results. After NCVI in patients with AH who had achieved the target ranges of office BP before its development, at home measurement and ABPM against the background of continuous antihypertensive therapy with high adherence to treatment, in more than 50 % of patients BP readings were not in the target values, in more than 50 % of the examined patients, BP variability was higher than the permissible values, in 73 % of patients the average daily BP was above 53 mm Hg. Abnormal patterns of circadian BP rhythm in patients with hypertension after NCVI were detected in 61.5 %: "Non-dipper" in 28.6 %; "Night-dipper" – in 21.9 %, masked nocturnal hypertension – in 17.1 %. Conclusion. The indicative significance of the development of abnormal patterns of circadian BP rhythm in patients with hypertension after NCVI was demonstrated by 3 qualitative indicators: glomerular filtration rate with cystatin C 60 ml/min/1.73 m2, cardio-ankle vascular index (CAVI) ≥ 9, and a high frequency of AGT gene polymorphism – T/T genotype (in 54.3 % of patients).

  • Open Access

    Patients With Non-Obstructive Coronary Artery Disease and Polyvascular Disease. Sub-Analysis of the Real-World Registry KAMMA (Clinical Registry on Patient Population With Polyvascular Disease in the Russian Federation and Eurasian Countries)

    by G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, T. I. Batluk, N. A. Koziolova, A. I. Chesnikova, A. Yu. Vaskin, D. S. Tokmin, I. G. Bakulin, O. L. Barbarash, et al.

    Aim. To study the clinical status and data of laboratory and instrumental examination of patients with non-obstructive ischemic heart disease (IHD) and multifocal atherosclerosis (MFA) included in the KAMMA registry. Material and methods. The subanalysis included 1,893 IHD patients who underwent coronary angiography (CAG) and ultrasonic examination of peripheral arteries. Based on the CAG data, patients were divided into two groups: group 1, patients with obstructive coronary atherosclerosis (CA) (maximum stenosis ≥50% and/or history of percutaneous coronary intervention/coronary artery bypass grafting, n=1728; 91.3%) and group 2, patients with non-obstructive CA (maximum stenosis Results. A comparative analysis based on the degree of coronary obstruction in patients with verified IHD who were included in the KAMMA registry showed that 8.7% of them had coronary artery stenosis of less than 50%. The overwhelming majority of patients with non-obstructive CA had MFA affecting the brachiocephalic arteries in 94.3% and the lower extremity arteries in 40.2%. Among patients with non-obstructive IHD, women predominated; risk factors such as smoking and type 2 diabetes mellitus were less frequent in this group than in the obstructive IHD group. Patients with non-obstructive CA more frequently had a history of dyslipidemia; they had higher total cholesterol and non-high-density lipoprotein cholesterol; and they more frequently received moderate-intensity statin therapy than patients with obstructive CA (55.8% vs. 34.5%). Characteristic features of patients with non-obstructive CA were less severe IHD and less frequent history of acute coronary syndrome. However, the incidence of stroke, peripheral arterial thrombosis, and chronic arterial insufficiency of the lower extremities did not differ in groups 1 and 2, whereas the incidence of paroxysmal atrial fibrillation was higher in the non-obstructive IHD group. Conclusion. IHD patients without coronary obstruction also require assessment of the peripheral arterial status, as they may have advanced MFA, which should be taken into account when choosing the “aggressiveness” of therapy.